A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HS-10502 Combination Treatment in Subjects with Advanced Solid Tumors
Latest Information Update: 16 Jan 2025
Price :
$35 *
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel (Primary) ; HS 10502 (Primary) ; HS-20089 (Primary) ; HS-20093 (Primary) ; Irinotecan (Primary) ; Paclitaxel (Primary) ; Platinum complexes (Primary) ; Rivoceranib (Primary)
- Indications Advanced breast cancer; Gastric cancer; HER2 negative breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Jiangsu Hansoh Pharmaceutical
- 16 Jan 2025 New trial record